Literature DB >> 12849005

Pathogenesis of heparin-induced thrombocytopenia and thrombosis.

Gowthami Arepally1, Douglas B Cines.   

Abstract

Heparin-induced thrombocytopenia and thrombosis (HIT/T) is a common immune-mediated disorder often manifested by life-threatening thrombosis. There is increasing evidence to indicate that HIT/T is caused by antibodies to complexes between platelet factor 4 (PF4) and heparin that activate platelets, monocytes and vascular endothelium leading to the generation of thrombin. Advances in defining the immunological basis of HIT/T have yielded insights into the antigenic determinants, antibody-antigen interactions and effector responses that contribute to its pathogenesis. However, these studies also reveal that anti-PF4/heparin antibodies develop far more commonly than clinically overt disease, raising questions as to serologic and other factors that predispose to clinical thrombocytopenia and thrombosis. An improved understanding of the natural history of HIT/T and the introduction of alternative anticoagulants have led to a somewhat improved clinical outcome. The recent development of a monoclonal anti-heparin/PF4 antibody and the establishment of a murine model of HIT/T may help to better define the pathogenesis and management of this common autoimmune disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12849005     DOI: 10.1016/s1568-9972(02)00031-9

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  9 in total

1.  Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Jessica D Hirsch; Teshell K Greene; Li Zhai; Vincent M Hayes; M Anna Kowalska; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

2.  Catastrophic thromboses and severe thrombocytopenia during heparin therapy in a patient with anti-phospholipid syndrome.

Authors:  Lior Zeller; Yaniv Almog; Ahron Tomer; Shaul Sukenik; Mahmoud Abu-Shakra
Journal:  Clin Rheumatol       Date:  2005-10-06       Impact factor: 2.980

3.  Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.

Authors:  Valerie Tutwiler; Daria Madeeva; Hyun Sook Ahn; Izabella Andrianova; Vincent Hayes; X Long Zheng; Douglas B Cines; Steven E McKenzie; Mortimer Poncz; Lubica Rauova
Journal:  Blood       Date:  2015-10-30       Impact factor: 22.113

4.  Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT.

Authors:  M Anna Kowalska; Sriram Krishnaswamy; Lubica Rauova; Li Zhai; Vincent Hayes; Karine Amirikian; Jeffrey D Esko; Daniel W Bougie; Richard H Aster; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

Review 5.  Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).

Authors:  Zheng Cai; Zhiqiang Zhu; Mark I Greene; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2016-03-09       Impact factor: 9.754

Review 6.  Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT).

Authors:  L Rauova; G Arepally; S E McKenzie; B A Konkle; D B Cines; M Poncz
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

7.  Heparin-induced thrombocytopenia: an update.

Authors:  Massimo Franchini
Journal:  Thromb J       Date:  2005-10-04

Review 8.  Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.

Authors:  Jason B Giles; Elise C Miller; Heidi E Steiner; Jason H Karnes
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

9.  Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia.

Authors:  Jason B Giles; Heidi E Steiner; Jerome Rollin; Christian M Shaffer; Yukihide Momozawa; Taisei Mushiroda; Chihiro Inai; Kathleen Selleng; Thomas Thiele; Claire Pouplard; Nancy M Heddle; Michiaki Kubo; Elise C Miller; Kiana L Martinez; Elizabeth J Phillips; Theodore E Warkentin; Yves Gruel; Andreas Greinacher; Dan M Roden; Jason H Karnes
Journal:  Blood Adv       Date:  2022-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.